Ahmad Sharayah, MD
Critical Care Medicine · Baton Rouge, LANPI 1871018150
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (58.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 60.9% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2024 at $9,627 and has fallen 80.8% since, to $1,852 in 2025. Among critical care medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $73.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Pulmonx Corporation$1K
- Sanofi$711
- GSK$487
- United Therapeutics Corporation$295
- Merck$260
- plus $2K from 27 others
What the payments were for
- Travel & lodging$9938%
- Food & beverage$3,97433%
- Education$7,10059%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $7,344 |
| Pulmonx Corporation | 7 | $1,016 |
| Sanofi | 21 | $711 |
| GSK | 25 | $487 |
| United Therapeutics Corporation | 8 | $295 |
| Merck | 12 | $260 |
| Boehringer Ingelheim | 13 | $255 |
| Inari Medical, Inc. | 1 | $162 |
| Grifols USA, LLC | 5 | $122 |
| Viatris Specialty LLC | 3 | $120 |
| Pfizer | 6 | $109 |
| Baxter Healthcare | 5 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| AstraZeneca | 5 | $99 |
| Verona Pharma, Inc. | 4 | $86 |
| Johnson & Johnson | 3 | $73 |
| Mylan Specialty L.p. | 3 | $71 |
| Insmed, Inc. | 3 | $69 |
| Electromed, Inc. | 9 | $65 |
| UCB, Inc. | 4 | $65 |
| AbbVie | 2 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Liquidia Technologies, Inc. | 2 | $41 |
| La Jolla Pharmaceutical Company | 2 | $41 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Inogen, Inc. | 2 | $33 |
| Philips North America LLC | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $27 |
| Coaptech, Inc. | 1 | $22 |
| Shionogi Inc | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,067 in reported general payments places this provider in the 90th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $38,707 |
| Spiriva RespimatTiotropium Bromide | 58 | $31,649 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,640 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $11,007 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,405 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,961 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,090 |
| Fluticasone Propionate | 30 | $369 |
| Pantoprazole Sodium | 18 | $138 |
| Prednisone | 25 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $255 | $42,65682 claims |
| GSKTrelegy Ellipta | $487 | $38,70757 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $99 | $16,04537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 critical care medicine providers in Louisiana.
Other critical care medicine in Baton Rouge
- Abdulla Majid-MoosaBaton Rouge$202K
- Ronald FieldsBaton Rouge$11K
- Merissa BraudBaton Rouge$8K
- James VermaelenBaton Rouge$8K
- Mostafa AboubakrBaton Rouge$6K
- James FordBaton Rouge$6K
- Vincent ValentineBaton Rouge$6K
- Daniel ReesBaton Rouge$4K
- Owen StellBaton Rouge$3K
- Dena LandryBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.